Calithera Biosciences Inc
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences Inc (CALA) - Total Liabilities
Latest total liabilities as of December 2022: $8.28 Million USD
Based on the latest financial reports, Calithera Biosciences Inc (CALA) has total liabilities worth $8.28 Million USD as of December 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Calithera Biosciences Inc - Total Liabilities Trend (2012–2022)
This chart illustrates how Calithera Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Calithera Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Calithera Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blackrock Smaller Companies Trust PLC
LSE:BRSC
|
UK | GBX76.83 Million |
|
SINOPEC SH PETRO-H- - Dusseldorf Stock Exchang
DU:SGJH
|
Germany | €20.35 Billion |
|
PACIFIC ONLINE
BE:4P7
|
Germany | €343.36 Million |
Liability Composition Analysis (2012–2022)
This chart breaks down Calithera Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Calithera Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Calithera Biosciences Inc (2012–2022)
The table below shows the annual total liabilities of Calithera Biosciences Inc from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $8.28 Million | -85.31% |
| 2021-12-31 | $56.37 Million | +142.82% |
| 2020-12-31 | $23.22 Million | -11.87% |
| 2019-12-31 | $26.34 Million | +64.52% |
| 2018-12-31 | $16.01 Million | -62.01% |
| 2017-12-31 | $42.15 Million | +761.92% |
| 2016-12-31 | $4.89 Million | +23.42% |
| 2015-12-31 | $3.96 Million | -10.04% |
| 2014-12-31 | $4.40 Million | -92.09% |
| 2013-12-31 | $55.66 Million | +378.52% |
| 2012-12-31 | $11.63 Million | -- |